2-(1-乙基哌啶-4-基)乙酸 | 915922-85-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(1-乙基哌啶-4-基)乙酸
• 英文名称: 2-(1-ethylpiperidin-4-yl)acetic acid
• 英文别名: (1-ethylpiperidin-4-yl)acetic acid；ethyl 4-carboxymethylpiperidine；(1-ethylpiperid-4-yl)acetic acid；2-(1-Ethylpiperidin-1-ium-4-yl)acetate
• CAS: 915922-85-9
• 化学式: C₉H₁₇NO₂
• mdl: MFCD08059874
• 分子量: 171.239
• InChiKey: DDHNVBMJTWHLJI-UHFFFAOYSA-N

物化性质

• 沸点：
  285.9±13.0 °C(Predicted)
• 密度：
  1.023±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-(1-乙基哌啶-4-基)乙酸 、 4-氯吡啶盐酸盐 在 三乙胺 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 二氯甲烷 为溶剂， 生成 ethyl 1-(4-pyridylpiperidin-4-yl)acetate
  参考文献：
  名称：

  Heterocyclic compouds

  摘要：

  通式（M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过粘附分子结合到GPIIb-IIIa介导的血小板聚集参与的疾病。还披露了新的化合物。

  公开号：

  US05753659A1
• 作为产物：
  描述：

  N-乙基-4-哌啶酮 在 盐酸 、 potassium carbonate 、 magnesium 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 40.58h， 生成 2-(1-乙基哌啶-4-基)乙酸
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists

  摘要：

  The ghrelin receptor is a G-protein-coupled receptor (GPCR) widely expressed in the brain, stomach and the intestine. It was firstly identified during studies aimed to find synthetic modulators of growth hormone (GH) secretion. GHSR and its endogenous ligand ghrelin were found to be involved in hunger response. Through food intake regulation, they could affect body weight and adiposity. Thus GHSR antagonists rapidly became an attractive target to treat obesity and feeding disorders. In this study we describe the biological properties of new indolinone derivatives identified as a new, chiral class of ghrelin antagonists. Their synthesis as well as the structure-activity relationship will be discussed herein. The in vitro identified compound 14f was a potent GHSR1a antagonist (IC50 = 7 nM). When tested in vivo, on gastric emptying model, 14f showed an inhibitory intrinsic effect when given alone and it dose dependently inhibited ghrelin stimulation. Compound 14f also reduced food intake stimulated both by fasting condition (high level of endogenous ghrelin) and by icv ghrelin. Moreover this compound improved glucose tolerance in ipGTT test. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.018

文献信息

• Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
  申请人：——

  公开号：US20030055244A1

  公开（公告）日：2003-03-20

  Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis

  本发明涉及某些含有取代或未取代吡啶基的螺环化合物，其取代有碱性和酸性功能，可用于抑制血小板聚集，抑制纤维蛋白原与血小板的结合，并预防或治疗血栓形成。
• FLUORESCENT PROBES FOR DETECTION OF COPPER
  申请人：The Regents Of The University Of California

  公开号：US20140051863A1

  公开（公告）日：2014-02-20

  The invention provides fluorescent sensors for the selective detection of a metal such as copper. The sensors may be considered to be derivatives of cyanine, fluorescein, rhodamine, rhodol, Tokyo green, or BODIPY. The sensors find particular use in detecting copper in cells and living animals.

  本发明提供了用于选择性地检测如铜等金属的荧光传感器。这些传感器可以被认为是青色素、荧光素、罗丹明、罗多醇、东京绿或BODIPY的衍生物。这些传感器在检测细胞和活体动物中的铜方面特别有用。
• INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BARONI Marco

  公开号：US20100210662A1

  公开（公告）日：2010-08-19

  The present invention relates to 3-disubstituted indol-2-one derivatives, to their preparation and to their therapeutic application.

  本发明涉及3-二取代吲哚-2-酮衍生物，它们的制备方法以及它们的药用应用。
• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05556977A1

  公开（公告）日：1996-09-17

  Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

  公式I的化合物及其代谢易降解的酯和酰胺，以及其药学上可接受的盐，其中R.sup.13，M.sup.2，X.sup.1，Z.sup.1，Z.sup.1a，X.sup.2和A.sup.1具有规范中给定的含义。这些化合物可用作抑制纤维蛋白原与糖蛋白IIb/IIIa结合的抑制剂。还披露了中间体。
• [EN] NANOMATERIALS<br/>[FR] NANOMATÉRIAUX
  申请人：GUIDE THERAPEUTICS INC

  公开号：WO2021141969A1

  公开（公告）日：2021-07-15

  Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve targeted delivery of therapeutic cargo without the need for a targeting ligand are also provided.

  描述了用于传递核酸的脂质纳米粒子组合物。在各种实施例中，脂质纳米粒子包含化学式（I）的可离子化脂质。还提供了使用这种脂质纳米粒子组合物实现靶向传递治疗载体而无需靶向配体的方法。